Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1848 2
1939 2
1947 2
1948 3
1950 5
1951 8
1952 15
1953 16
1954 10
1955 4
1956 1
1957 4
1958 1
1959 2
1960 6
1961 3
1962 4
1963 7
1964 7
1965 11
1966 16
1967 9
1968 11
1969 20
1970 12
1971 17
1972 21
1973 20
1974 13
1975 16
1976 11
1977 13
1978 11
1979 12
1980 3
1981 10
1982 10
1983 13
1984 20
1985 15
1986 14
1987 9
1988 19
1989 17
1990 19
1991 18
1992 17
1993 11
1994 10
1995 18
1996 15
1997 18
1998 20
1999 22
2000 21
2001 19
2002 19
2003 13
2004 10
2005 11
2006 14
2007 27
2008 33
2009 26
2010 32
2011 32
2012 35
2013 32
2014 25
2015 22
2016 25
2017 32
2018 28
2019 14
2020 15
2021 26
2022 13
2023 29
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

1,104 results

Results by year

Filters applied: . Clear all
Page 1
Antifibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4-associated Tissue Repair Macrophages.
Watson CK, Schloesser D, Fundel-Clemens K, Lerner C, Gabler S, Baskaran P, Wohnhaas CT, Dichtl S, Huber HJ, Ask K, Gantner F, Viollet C, Thomas MJ, Ramirez F, Murray PJ, El Kasmi KC. Watson CK, et al. Among authors: huber hj. Am J Respir Cell Mol Biol. 2023 Apr;68(4):366-380. doi: 10.1165/rcmb.2022-0021OC. Am J Respir Cell Mol Biol. 2023. PMID: 36227799
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Huber H, Tausch E, Schneider C, Edenhofer S, von Tresckow J, Robrecht S, Giza A, Zhang C, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Al-Sawaf O, Kreuzer KA, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Huber H, et al. Blood. 2023 Sep 14;142(11):961-972. doi: 10.1182/blood.2023020013. Blood. 2023. PMID: 37363867
Transcranial sonography--anatomy.
Huber H. Huber H. Int Rev Neurobiol. 2010;90:35-45. doi: 10.1016/S0074-7742(10)90003-2. Int Rev Neurobiol. 2010. PMID: 20692492 Review.
Efficacy and safety of antenatal steroids.
Kemp MW, Jobe AH, Usuda H, Nathanielsz PW, Li C, Kuo A, Huber HF, Clarke GD, Saito M, Newnham JP, Stock SJ. Kemp MW, et al. Among authors: huber hf. Am J Physiol Regul Integr Comp Physiol. 2018 Oct 1;315(4):R825-R839. doi: 10.1152/ajpregu.00193.2017. Epub 2018 Apr 11. Am J Physiol Regul Integr Comp Physiol. 2018. PMID: 29641233 Free article. Review.
Archaeal symbionts and parasites.
Moissl-Eichinger C, Huber H. Moissl-Eichinger C, et al. Among authors: huber h. Curr Opin Microbiol. 2011 Jun;14(3):364-70. doi: 10.1016/j.mib.2011.04.016. Epub 2011 May 14. Curr Opin Microbiol. 2011. PMID: 21571580 Review.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, Schneider C, Bloehdorn J, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Huber H, et al. Blood. 2022 Mar 3;139(9):1318-1329. doi: 10.1182/blood.2021013208. Blood. 2022. PMID: 35108374 Free article. Clinical Trial.
Recognition of the unsuitability of DSM 12173 as the deposited type strain of Thermocrinis ruber Huber et al. 1999, recognition of DSM 23557 as an authentic sub-culture of strain OC 1/4, the nomenclatural type of Thermocrinis ruber Huber et al. 1999 and an emended description of Thermocrinis ruber Huber et al. 1999.
Eder W, Tindall BJ, Huber H, Peplies J, Wirth R. Eder W, et al. Among authors: huber h. Arch Microbiol. 2020 Aug;202(6):1559-1562. doi: 10.1007/s00203-020-01850-x. Epub 2020 Mar 14. Arch Microbiol. 2020. PMID: 32172288
Epithelial-mesenchymal transition in hepatocellular carcinoma.
van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H, Mikulits W. van Zijl F, et al. Among authors: huber h. Future Oncol. 2009 Oct;5(8):1169-79. doi: 10.2217/fon.09.91. Future Oncol. 2009. PMID: 19852728 Free PMC article. Review.
1,104 results